The drum­beat of Alzheimer’s PhI­II fail­ures con­tin­ues as vTv drug is out­per­formed by a place­bo, shares crash

The ex­ecs at vTv $VTVT have put an­oth­er nail in the cof­fin of re­cy­cled Alzheimer’s drug pro­grams.

The biotech, which float­ed an IPO on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.